Key Takeaways IOVA posted a wider Q2 loss of $0.33 per share and revenue of$60M, both missing estimates.Amtagvi sales rose to $54.1M, but the EU filing was withdrawn over data alignment issues with the EMA.IOVA announced a restructuring to cut 19$100M in annual cost savings.Iovance Biotherapeutics (IOVA) incurred a second-quarter 2025 loss of 33 cents per share, wider than the Zacks Consensus Estimate of a loss of 29 cents. In the year-ago quarter, the company reported a loss of 34 ce ...